Clinical trial
Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus
NCT00453375 · Bayhill Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00453375 |
|---|---|
| Title | Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus |
| Official title | A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 With Open Label Cross-Over in Subjects With Type I Diabetes Mellitus |
| Lead sponsor | Bayhill Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetes, Hypoglycemia |
| Intervention type | Drug |
| Interventions | BHT-3021, BHT-Placebo |
| Enrollment | 80 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Mar 28, 2007 |
| Last update posted | Jun 28, 2011 |
| Countries | Australia, New Zealand, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: